Search Results 901-910 of 17226 for presbyopia

  1. Transient ischemic attack (TIA) - Doctors and departments - Mayo Clinic

    This short bout of stroke-like symptoms doesn't cause permanent damage. But it may serve as a warning sign of a future stroke.

  2. Surgery - Doctors - Mayo Clinic

    Mayo Clinic Surgery offers deep expertise and a wide range of surgical care to tens of thousands of people each year.

  3. Neurosurgery - Clinical trials

    Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6- ...

  4. Tween and teen health

    If your child needs to move more, suggest team sports or other ways to stay active. Also encourage your teen or tween to eat healthy foods. Offer nutritious ...

  5. Mayo Clinic

    ... . IMG-20076709. Home; DE00010Clearinguprootcanalinfection. 3X your impact! Give Now! Your gift can go 3X as far to shape the future of cancer care.

  6. A Study to Evaluate the Safety and Tolerability of HMPL-306 to Treat Advanced or Metastatic Solid Tumors with IDH Mutations - Mayo Clinic

    The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of HMPL-306 in advanced or metastatic solid tumors with IDH ...

  7. Transient ischemic attack (TIA) - Doctors and departments - Mayo Clinic

    This short bout of stroke-like symptoms doesn't cause permanent damage. But it may serve as a warning sign of a future stroke.

  8. Research Experiences for Teachers Program - Applications

    The application cycle for the 2026 Research Experiences for Teachers Program cohort begins Dec. 8, 2025, and closes Jan. 17, 2026.

  9. Obstructive sleep apnea - Doctors and departments - Mayo Clinic

    Mayo Clinic experts trained in sleep medicine study new diagnosis and treatment options for obstructive sleep apnea, sleep-disordered breathing and other sleep ...

  10. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer - Mayo Clinic

    For the dose that meets the safety criterion in Stage 1, at least 1 response in melanoma subjects and 2 responses in TNBC subjects amongst the 12 subjects ...